New drug aims to clear hepatitis b in HIV patients

NCT ID NCT06497504

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study tests a new drug called bepirovirsen in 153 people who have both HIV and chronic hepatitis B and are already on HIV treatment. The goal is to see if bepirovirsen can clear the hepatitis B virus from the body better than a placebo. Participants will continue their regular HIV medications throughout the study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS chronic hepatitis B virus infection hepatitis B virus infection HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B

Contacts and locations

Locations

GSK Investigational Site

Bakersfield, California, 93301, United States
GSK Investigational Site

San Francisco, California, 94115, United States
GSK Investigational Site

Orlando, Florida, 32803, United States
GSK Investigational Site

West Palm Beach, Florida, 33409, United States
GSK Investigational Site

Baltimore, Maryland, 21287, United States
GSK Investigational Site

Minneapolis, Minnesota, 55415, United States
GSK Investigational Site

Hillsborough, New Jersey, 08844, United States
GSK Investigational Site

Almagro, C1427CEA, Argentina
GSK Investigational Site

Buenos Aires, 1023, Argentina
GSK Investigational Site

Buenos Aires, C1181ACI, Argentina
GSK Investigational Site

Buenos Aires, C1425AGC, Argentina
GSK Investigational Site

La Plata, B1900AVG, Argentina
GSK Investigational Site

Rosario, S2002KDR, Argentina
GSK Investigational Site

Aracaju, 49060-010, Brazil
GSK Investigational Site

Campinas, 13034-685, Brazil
GSK Investigational Site

Curitiba, 80810-050, Brazil
GSK Investigational Site

Manaus, 69040-000, Brazil
GSK Investigational Site

Salvador, 40110-060, Brazil
GSK Investigational Site

São Paulo, 04121-000, Brazil
GSK Investigational Site

Ottawa, Ontario, K1H 8L6, Canada
GSK Investigational Site

Toronto, Ontario, M5G 1K2, Canada
GSK Investigational Site

Montreal, Quebec, H2L 4P9, Canada
GSK Investigational Site

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site

Québec, Quebec, G1V 4G2, Canada
GSK Investigational Site

Marseille, 13003, France
GSK Investigational Site

Melun, 77000, France
GSK Investigational Site

Montpellier, 34295, France
GSK Investigational Site

Nantes, 44093, France
GSK Investigational Site

Paris, 75012, France
GSK Investigational Site

Paris, 75018, France
GSK Investigational Site

Genova, 16132, Italy
GSK Investigational Site

Milan, 20157, Italy
GSK Investigational Site

Milan, 20162, Italy
GSK Investigational Site

Naples, 80131, Italy
GSK Investigational Site

Roma, 00153, Italy
GSK Investigational Site

Sassari, 07100, Italy
GSK Investigational Site

Durban, KwaZulu-Natal, 4052, South Africa
GSK Investigational Site

Ekurhuleni, 1459, South Africa
GSK Investigational Site

Johannesburg, 2092, South Africa
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Córdoba, 14004, Spain
GSK Investigational Site

Madrid, 28032, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Banchiau Taipei, 220, Taiwan
GSK Investigational Site

Kaohsiung City, 813, Taiwan
GSK Investigational Site

Bristol Avon, BS10 5NB, United Kingdom
GSK Investigational Site

London, E1 1BB, United Kingdom
GSK Investigational Site

London, NW3 2QG, United Kingdom
GSK Investigational Site

London, SE5 9RS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.